$BZYR
BURZYNSKI RESEARCH INSTITUTE INC

2022 Q1 Form 10-Q Financial Statement

#000155837022000267 Filed on January 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $43.84K $50.66K $38.30K
YoY Change -12.32% 48.17% -51.56%
% of Gross Profit
Research & Development $127.0K $214.1K $186.4K
YoY Change -36.48% -6.96% -25.28%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $170.9K $264.8K $224.7K
YoY Change -31.65% 0.17% -31.6%
Operating Profit -$264.8K -$224.7K
YoY Change 0.17% -31.6%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$170.9K -$264.8K -$224.7K
YoY Change 13.92% 0.17% -31.6%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$170.9K -$264.8K -$224.7K
YoY Change 13.92% 0.17% -31.6%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share -$1.300K $0.00 -$1.710K
COMMON SHARES
Basic Shares Outstanding 131.4M 131.4M 131.4M
Diluted Shares Outstanding 131.4M 131.4M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.380K $5.770K $900.00
YoY Change 439.25% -47.37%
Cash & Equivalents $3.382K $5.765K $904.00
Short-Term Investments
Other Short-Term Assets $1.280K $970.00 $940.00
YoY Change -9.35% -24.8%
Inventory
Prepaid Expenses $1.279K $974.00 $936.00
Receivables
Other Receivables
Total Short-Term Assets $4.661K $6.739K $1.840K
YoY Change 387.55% 214.91% -37.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $4.661K $6.739K $1.840K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $4.661K $6.739K $1.840K
YoY Change 387.55% 214.91% -37.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00 $1.389K $19.26K
YoY Change -100.0% -93.57% -77.64%
Accrued Expenses $3.455K $0.00 $10.41K
YoY Change -75.82% -100.0% -91.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.460K $1.390K $29.67K
YoY Change -93.08% -98.94% -85.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.460K $1.390K $29.67K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.455K $1.389K $29.67K
YoY Change -92.62% -98.94% -85.48%
SHAREHOLDERS EQUITY
Retained Earnings -$125.8M -$125.7M -$125.4M
YoY Change 0.78%
Common Stock $125.8M $125.7M $125.4M
YoY Change 0.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.206K $5.350K -$27.83K
YoY Change
Total Liabilities & Shareholders Equity $4.661K $6.739K $1.840K
YoY Change 387.55% 214.91% -37.84%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q3
OPERATING ACTIVITIES
Net Income -$170.9K -$264.8K -$224.7K
YoY Change 13.92% 0.17% -31.6%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$58.10K -$95.16K -$87.40K
YoY Change 28.11% -23.17% -36.35%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.72K 100.0K 87.71K
YoY Change 25.35% -18.83% -36.9%
NET CHANGE
Cash From Operating Activities -58.10K -95.16K -87.40K
Cash From Investing Activities
Cash From Financing Activities 55.72K 100.0K 87.71K
Net Change In Cash -2.380K 4.860K 310.0
YoY Change 164.44% -859.37% -81.76%
FREE CASH FLOW
Cash From Operating Activities -$58.10K -$95.16K -$87.40K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Entity Registrant Name
EntityRegistrantName
BURZYNSKI RESEARCH INSTITUTE INC
dei Entity Central Index Key
EntityCentralIndexKey
0000724445
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
CY2020Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
dei Security Exchange Name
SecurityExchangeName
NONE
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-11-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-23425
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0136810
dei Entity Address Address Line1
EntityAddressAddressLine1
9432 Katy Freeway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77055
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
335-5697
dei Security12b Title
Security12bTitle
None
dei Trading Symbol
TradingSymbol
BZYR
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131448444
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5765
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
974
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
894
CY2021Q4 us-gaap Assets Current
AssetsCurrent
6739
CY2021Q1 us-gaap Assets Current
AssetsCurrent
956
CY2021Q4 us-gaap Assets
Assets
6739
CY2021Q1 us-gaap Assets
Assets
956
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1389
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
32512
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14287
CY2021Q4 us-gaap Liabilities
Liabilities
1389
CY2021Q1 us-gaap Liabilities
Liabilities
46799
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
131449
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
131449
us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125541505
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
124684535
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125667604
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124861827
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5350
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-45843
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6739
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
956
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
214112
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
230131
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50664
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34194
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
264776
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
264325
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-264776
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-264325
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-264776
CY2020Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-264325
CY2021Q4 us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
CY2020Q4 us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-264776
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-264325
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2020Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2020Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
632475
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
819297
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
173302
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
231538
us-gaap Operating Expenses
OperatingExpenses
805777
us-gaap Operating Expenses
OperatingExpenses
1050835
us-gaap Operating Income Loss
OperatingIncomeLoss
-805777
us-gaap Operating Income Loss
OperatingIncomeLoss
-1050835
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-805777
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1050835
us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-805777
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1050835
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-45843
CY2021Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
84967
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
215926
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-316283
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-61233
CY2021Q3 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
87717
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
170403
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-224718
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-27831
CY2021Q4 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
100017
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
197940
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-264776
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5350
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-152587
CY2020Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
83317
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
281978
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-457970
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-245262
CY2020Q3 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
139017
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
233399
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-328540
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-201386
CY2020Q4 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
123217
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
213462
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-264325
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-129032
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-805777
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1050835
bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
584270
bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
728839
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
80
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-18617
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-31123
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-39201
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14287
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2065
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-266997
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-344645
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
272701
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
345551
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
272701
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
345551
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5704
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
906
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5766
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1069
CY2021Q4 bzyr Ownership Interest Percentage Held By Company President And Chairman Of Board
OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard
0.810
bzyr Number Of Antineoplaston Drugs That Received Fda Approval
NumberOfAntineoplastonDrugsThatReceivedFDAApproval
0
us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
169213
us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
220675
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-10751
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-4947
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10751
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4947
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
157831
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
bzyr Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
1
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
CY2020Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
CY2021Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q4 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-55603
CY2020Q4 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-55508
CY2021Q4 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
55603
CY2020Q4 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
55508
CY2021Q4 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-6968
CY2020Q4 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-15195
CY2021Q4 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6968
CY2020Q4 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15195
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-169213
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-220675
us-gaap Revenues
Revenues
0
bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
bzyr Net Operating Loss Carry Forward Indefinitely
NetOperatingLossCarryForwardIndefinitely
78948

Files In Submission

Name View Source Status
0001558370-22-000267-index-headers.html Edgar Link pending
0001558370-22-000267-index.html Edgar Link pending
0001558370-22-000267.txt Edgar Link pending
0001558370-22-000267-xbrl.zip Edgar Link pending
bzyr-20211130.xsd Edgar Link pending
bzyr-20211130x10q.htm Edgar Link pending
bzyr-20211130x10q_htm.xml Edgar Link completed
bzyr-20211130xex31d1.htm Edgar Link pending
bzyr-20211130xex31d2.htm Edgar Link pending
bzyr-20211130xex32d1.htm Edgar Link pending
bzyr-20211130xex32d2.htm Edgar Link pending
bzyr-20211130_cal.xml Edgar Link unprocessable
bzyr-20211130_def.xml Edgar Link unprocessable
bzyr-20211130_lab.xml Edgar Link unprocessable
bzyr-20211130_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending